Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children.
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2014
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors sanofi pasteur
- 15 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Feb 2010 Planned end date changed from 1 Jun 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
- 28 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.